European Pharmaceutical Review

FEBRUARY 22, 2023

Although effective, the inconvenience of regular injections can lead to poor patient adherence, with studies showing that persistence and adherence are generally better for oral medications compared with injections. Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

Veeva

FEBRUARY 6, 2022

According to Veeva Pulse data , COVID-19 has accelerated the shift to digital for life sciences, with significant growth in remote and digital engagement since early 2020, and a 10X increase of HCPs using three or more channels in their engagement with pharma 1. Get stakeholder buy in on the “why”. About Veeva.

Pharma 52

Pharma Medical Consulting Patients 52

European Pharmaceutical Review

MAY 2, 2023

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. He received an MD from the Georg August University of Göttingen and completed a postdoctoral Master’s in Medical Sciences Clinical Pharmacology at the University of Glasgow.

Patients 105

Patients Medicine Marketing Medical 105

European Pharmaceutical Review

DECEMBER 28, 2023

About the interviewee Dr Andreas Harstrick joined Affimed as CMO in 2020, bringing with him more than 30 years of experience and expertise in cancer drug development, clinical trial research, and regulatory approvals. Andreas held several senior executive roles, including Senior Vice President of Medical Sciences at ImClone Systems, Inc.,

Food and Drug Administration 84

Food and Drug Administration Patients Safety Medical science 84

European Pharmaceutical Review

AUGUST 15, 2024

1 The cancer is a slow-growing but potentially life-threatening B-cell malignancy, in which increased activation of B-cell receptor signalling pathways leads to overgrowth of lymphocytes in bone marrow and other disease compartments. About the author Dr Mehrdad Mobasher, MPH, is the Chief Medical Officer for Hematology at BeiGene.

Safety 52

Safety Patients Medical Medicine 52

Evolve Your Success

OCTOBER 31, 2023

It’s hard to divvy all that because we work with medical affairs and medical science liaisons. Honestly, because it’s temporary, when we get ready to take out the temporary leads, some of the patients are like, “I don’t want that removed.” We have two managers. It’s such a broad team.

Engineering 130

Engineering Sales Medical sales Medical 130